NK Cell-derived Exosomes from NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-Activated NK Cells

Journal of Immunotherapy

Volumn 40, Issue 7, 2017, Pages 265-276

  Shoae Hassani, Alireza ^a   Hamidieh, Amir Ali ^a,b   Behfar, Maryam ^b   Mohseni, Rashin ^a   Mortazavi Tabatabaei, Seyed A ^a   Asgharzadeh, Shahab ^c,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Oncology and Blood and Marrow Transplantation   (Iran)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

cancer therapy; exosome; immune cell therapy; natural killer cell; neuroblastoma; peripheral blood

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 21; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; BIOLOGICAL MARKER; CYTOKINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL EXPANSION; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DOWN REGULATION; EXOSOME; FILTRATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOPARTICLE TRACKING ANALYSIS; NATURAL KILLER CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TUMOR VOLUME; ULTRACENTRIFUGATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOKINE ACTIVATED KILLER CELL; METABOLISM; MORTALITY; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BIOMARKERS; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EXOSOMES; HETEROGRAFTS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; MALE; MICE; NEUROBLASTOMA; PHENOTYPE; RECEPTORS, NATURAL KILLER CELL; TUMOR BURDEN;

EID: 85020529022     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000179     Document Type: Article

References (46)

1. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. Distribution of reactivity and specificity. Int J Cancer. 1975;16:216-229.
2. Curti A, Ruggeri L, Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118:3273-3279.
3. Geller MA, Cooley S, Judson PL, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011; 13:98-107.
4. Iliopoulou EG, Kountourakis P, Karamouzis MV, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1781-1789.
5. Garg TK, Szmania SM, Khan JA, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012;97:1348-1356.
6. Zhang H, Cu Y, Voong N, et al. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother. 2011;34:187-195.
7. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595-601.
8. Kasaian MT, Whitters MJ, Carter LL, et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: A mediator of the transition from innate to adaptive immunity. Immunity. 2002;16:559-569.
9. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57-63.
10. Cooper MA, Fehniger TA, Caliguiri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;11:633-640.
11. Fais S. NK cell-released exosomes. Oncoimmunology. 2013; 2:e22337.
12. Parolini I, Federici C, Raggi C, et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009;284:34211-34222.
13. Ashiru O, Boutet P, Fernández-Messina L, et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA∗008 that is shed by tumor cells in exosomes. Cancer Res. 2010;70:481-489.
14. Zech D, Rana S, Büchler MW, et al. Tumor-exosomes and leukocyte activation: An ambivalent crosstalk. Cell Commun Signal. 2012;10:37-43.
15. Reiners KS, Topolar D, Henke A, et al. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-Tumor activity. Blood. 2013;121:3658-3665.
16. Muller L, Mitsuhashi M, Simms P, et al. Tumor-derived exosomes regulate expression of immune function related genes in human T cell subsets. Sci Rep. 2016;6:20254.
17. Lugini L, Cecchetti S, Huber V, et al. Immune surveillance properties of human NK cell-derived exosomes. J Immunol. 2012;189:2833-2842.
18. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010-4017.
19. Shoae-Hassani A, Keyhanvar P, Seifalian AM, et al. lambda Phage nanobioparticle expressing apoptin efficiently suppress human breast carcinoma tumor growth in vivo. PLoS One. 2013;8:e79907.
20. Ho YS, Yu MS, Lai CSW, et al. Characterizing the neuroprotective effects of alkaline extract of Lycium barbarum on betaamyloid peptide neurotoxicity. Brain Res. 2007;1158:123-134.
21. Sanchez CJ, Le Treut T, Boehrer A, et al. Natural killer cells and malignant haemopathies: A model for the interaction of cancer with innate immunity. Cancer Immunol Immunother. 2011;60:1-13.
22. Decot V, Voillard L, Latger-Cannard V. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Exp Hematol. 2010;38:351-362.
23. Pillet AH, Bucault F, Theze J, et al. A programmed switch from IL-15-To IL-2-dependent activation in human NK cells. J Immunol. 2009;182:6267-6277.
24. Park YP, Choi SC, Kiesler P. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the gc cytokines and TGF-b1. Blood. 2011;118:3019-3027.
25. Cheng M, Chen Y, Xiao W, et al. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 2013;10: 230-252.
26. Koch J, Steinle A, Watzl C, et al. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol. 2013;34:182-191.
27. Ahmed KA, Xiang J. Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med. 2011;15:1458-1473.
28. Gesierich S, Berezovskiy I, Ryschich E, et al. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res. 2006;66:7083-7094.
29. Nazarenko I, Rana S, Baumann A, et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosomeinduced endothelial cell activation. Cancer Res. 2010;70:1668-1678.
30. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014;3:1-8.
31. Chaput N, Flament C, Viaud S, et al. Dendritic cell derivedexosomes: biology and clinical implementations. J Leukoc Biol. 2006;80:471-478.
32. Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3:9.
33. Skog J. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470-1476.
34. Zhu S, Phatarpekar PV, Denman CJ, et al. Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood. 2014;124:403-411.
35. Somanchi SS, Senyukov VV, Denman CJ, et al. Expansion, purification, and functional assessment of human peripheral blood NK cells. J Vis Exp. 2011;48:2540.
36. Denman CJ, Senyukov VV, Somanchi SS, et al. Membranebound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7:e30264.
37. Liu Y, Wu HW, Sheard MA, et al. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res. 2013;19:2132-2143.
38. Robbins SH, Nguyen KB, Takahashi N, et al. Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells. J Immunol. 2002;168:2585-2589.
39. Yang Y, Han Q, Hou Z, et al. Exosomes mediate hepatitis B virus (HBV) transmission and NK-cell dysfunction. Cell Mol Immunol. 2017;14:465-475.
40. Li J, Liu K, Liu Y, et al. Exosomes mediate the cell-To-cell transmission of IFN-Alpha-induced antiviral activity. Nat Immunol. 2013;14:793-803.
41. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol. 2001;19:291-330.
42. Colucci F, Di Santo JP, Leibson PJ. Natural killer cell activation in mice and men: different triggers for similar weapons? Nat Immunol. 2002;3:807-813.
43. Bretz NP, Ridinger J, Rupp AK, et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem. 2013; 288:36691-36702.
44. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev. 2006;17:325-337.
45. Baj-Krzyworzeka M. Tumor-derived microvesicles carry several surface determinants and MRNA of tumor cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother. 2006;55:808-818.
46. Cooper MA, Elliott JM, Keyel PA, et al. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A. 2009;106:1915-1919.